Tecentriq combination fails to improve survival in metastatic lung cancer
Click Here to Manage Email Alerts
Tiragolumab plus atezolizumab added to chemotherapy did not extend survival outcomes as first-line therapy of locally advanced unresectable or metastatic non-squamous non-small cell lung cancer, interim results from a randomized study showed.
Results from the phase 2/phase 3 SKYSCRAPER-06 trial revealed the atezolizumab-led regimen to be less effective than pembrolizumab and chemotherapy. The investigative regimen missed the study’s primary end points by failing to improve PFS or OS, according to topline data released by the manufacturer.
Tiragolumab (Genentech, Roche) is an investigational immune checkpoint inhibitor that binds to T cell immunoglobulin and ITIM domain (TIGIT) receptor, whereas atezolizumab (Tecentriq; Genentech, Roche) is an anti-PD-L1 monoclonal antibody approved for several lung cancer indications, inducing metastatic disease.
“Dual blockade with tiragolumab and Tecentriq may help overcome immune suppression and restore the immune response,” according to a Roche press release.
A primary analysis of results from SKYSCRAPER-06 showed tiragolumab plus atezolizumab and chemotherapy did not meet its co-primary endpoint of PFS (HR = 1.27; 95% CI, 1.02-1.57) compared with pembrolizumab and chemotherapy as first-line treatment for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer. The atezolizumab-led regimen failed to meet its other co-primary endpoint of OS during an interim analysis using immature data (HR = 1.33; 95% CI, 1.02, 1.73].
“These results are disappointing as it was our hope that this combination might yield improved outcomes for people living with metastatic non-squamous lung cancer,” Levi Garraway, MD, PhD, chief medical officer and head of global product development at Roche, said in a company-issued press release. “We are thankful to all of the patients and healthcare professionals involved in the study, and we will leverage the learnings to inform our scientific understanding of the anti-TIGIT pathway and new avenues in cancer research.”
Click Here to Manage Email Alerts